-
Study Findings Demonstrate Clinical Response with REMICADE in Pediatric Patients Who Have Not Responded to Conventional Therapy (JNJ)
Monday, May 9, 2011 - 4:35pm | 132J&J (NYSE: JNJ) unit says remicade phase 3 is effective.Data from a Phase 3 randomized, multicenter, open-label study demonstrated clinical response with REMICADE® (infliximab) in the treatment of pediatric patients with moderately to severely active ulcerative colitis, and showed a safety...
-
Forest Laboratories Receives Subpoena on Benicar®, Benicar HCT® and Azor® (FRX)
Monday, May 9, 2011 - 4:08pm | 79Forest Laboratories, Inc. (NYSE: FRX) announced that it received a subpoena from the Office of the U.S. Attorney for the District of Massachusetts dated April 20, 2011. The subpoena requests documents relating to Benicar®, Benicar HCT® and Azor®, prescription medications approved for the treatment...
-
Avanir Pharmaceuticals Reports EPS of $(0.12) vs. $(0.14) Estimate; Revenues $1.4M vs. $2.75M Estimate
Monday, May 9, 2011 - 4:02pm | 22Avanir Pharmaceuticals (NASDAQ: AVNR) Reports EPS of $(0.12) vs. $(0.14) Estimate; Revenues $1.4M vs. $2.75M Estimate
-
Calls Purchased on ViroPharma Incorporated (VPHM)
Monday, May 9, 2011 - 3:34pm | 124Shares of ViroPharma Incorporated (NASDAQ: VPHM) are higher on the session by 1.75%, currently trading at $19.20. The stock has been moving largely higher over the past six months and is currently trading above the 200-day moving average. Options traders are buying calls on the name today. A...
-
Options Brief: Medicis Pharmaceutical Corporation (MRX)
Monday, May 9, 2011 - 2:03pm | 92Shares of Medicis Pharmaceutical Corporation (NYSE: MRX) are higher on the session by 0.39%, trading at $38.45. Overall call volume is now running at 3.62x the daily average, with 52% of all calls traded being purchases on the offer. 1,886 contracts have traded on the session so far. Medicis...
-
Optimer Pharmaceuticals Announces Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID Phase 3 Data
Monday, May 9, 2011 - 1:02pm | 148Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the presentation of two abstracts at the 2011 Digestive Disease Week conference highlighting additional analyses of data from Phase 3 trials of DIFICID, an investigational product for the treatment of Clostridium difficile infection....
-
UPDATE: Hapoalim Raising Price Target On Alkermes (ALKS)
Monday, May 9, 2011 - 12:38pm | 308Hapoalim Securities is maintaining its Buy rating and raising its price target on shares of Alkermes (NASDAQ: ALKS) to $20 from $17 after the company did a deal with Elan (NYSE: ELN). In a note to clients, Hapoalim writes, "Alkermes and Elan Corporation announced that Alkermes will merge with Elan...
-
Forest and Almirall to Present Data from Phase III Studies of Aclidinium Bromide in Chronic Obstructive Pulmonary Disease
Monday, May 9, 2011 - 12:00pm | 124Forest Laboratories, Inc. (NYSE: FRX) and Almirall, S.A. today announced that they are presenting additional data from ATTAIN, a pivotal Phase III study comparing the efficacy and safety of inhaled aclidinium bromide 200μg and 400μg twice daily (BID) versus placebo in patients with moderate to...
-
Valeant CEO Says Not Ruling Out Future Hostile Bids and $500M Remaining in Buyback Program (VRX, CEPH)
Monday, May 9, 2011 - 11:34am | 50Valeant (NYSE: VRX) CEO says, "disappointed in Cephalon (NASDAQ: CEPH) outcome.... in `active discussions' with potential targets... no urgency to pursue any acquisition... not ruling out future hostile bids... $500M remaining in buyback program."
-
Benzinga's Volume Movers (ALKS, NUAN, BSFT, ROSE)
Monday, May 9, 2011 - 10:26am | 190Alkermes Inc (NASDAQ: ALKS) shares moved up 4.94% to $15.19 at 10:25 am. The volume of ALKS shares traded was 388% higher than normal. Alkermes Inc (NASDAQ: ALKS) announced its plans to merge with Elan Drug Technologies, the drug formation and manufacturing unit of Elan Corp. PLC (NYSE: ELN) in a...
-
Dividend Champion Portfolio for May
Monday, May 9, 2011 - 9:48am | 360Get MarketClub's Free Daily Video Market Updates Here Follow me on Twitter! I have updated the Dividend Champion Portfolio for May. The full commentary can be viewed here. I began tracking the portfolio in December and to date it is up 9.66% including dividends. For May 9th, the portfolio will...
-
Warner Chilcott Cited by U.S. FDA Over Youtube Ad for Atelvia -Bloomberg (WCRX)
Monday, May 9, 2011 - 9:44am | 25Bloomberg reports that Warner Chilcott (NASDAQ: WCRX) cited by U.S. FDA over Youtube ad for Atelvia.
-
Avanir Pharmaceuticals Announces Appointment of Elona Kogan, Esq. as Vice President of Legal Affairs (AVNR)
Monday, May 9, 2011 - 8:35am | 186Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the appointment of Elona Kogan, Esq. to the position of vice president of legal affairs. "At this time of growth and transition to a commercial stage biopharmaceutical company, Elona's legal, regulatory and business expertise will be a...
-
Benzinga's Top Downgrades (ASEI, TE, OMPI, GSIC)
Monday, May 9, 2011 - 8:28am | 145Benchmark Company downgraded American Science and Engineering Inc (NASDAQ: ASEI) from “buy” to “hold.” ASEI's shares closed at $87.33 on Friday. American Science and Engineering's PEG ratio is 1.53. Bank of America downgraded TECO Energy (NYSE: TE) from “neutral” to “underperform.” TE's stock...
-
Valeant Pharma Reports EPS of $0.62 vs. $0.58 a Year Ago Revenues $565M vs. $297.1M Estimate (VRX)
Monday, May 9, 2011 - 8:04am | 24Valeant Pharma (NYSE: VRX) Reports EPS of $0.62 vs. $0.58 a Year Ago Revenues $565M vs. $297.1M Estimate